HTX-011: Another game changer multimodal analgesic or an ephemeral, experimental drug!

Nair, Abhijit; Mantha, Srinivasa Shyam Prasad; Suvvari, Praneeth; Anne, Poornachand

doi:10.4103/sja.sja_227_20

Cited by 3 publications

(2 citation statements)

References 7 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The various local anesthetic delivery systems and their applications are summarized in Table 1 . In recent years, although domestic and foreign research in drug sustained-release formulations has made certain advancements, especially in the fields of antitumor drugs and antibiotics, and the FDA has also approved four types of local anesthetic-related retardant dosage forms, Exparel™, Xaracoll™, Posimir™, and Zynrelef™, for clinical applications, but their clinical translation still faces difficulties (Cusack et al., 2012 ; Hadj et al., 2012 ; Alijanipour et al., 2017 ; Amundson et al., 2017 ; Coppens et al., 2019 ; Velanovich et al., 2019 ; Nair et al., 2020 ; Blair, 2021 ; Chaurasiya et al., 2021 ; Leiman et al., 2021 ; Pedoto et al., 2021 ; Ekelund et al., 2022 ; Otremba et al., 2022 ; Gailey & Ostrum, 2023 ; Yu et al., 2023 ) ( Table 2 ). In recent years, local anesthetic control agents have also proliferated, such as mesoporous silica-coated gold nanorods controlled by infrared light and thermosensitive graphene oxide/chitosan-based nanocomposite hydrogels in local anesthetics; however, no FDA-approved local anesthetic control agents are available for clinical applications (Wang H et al., 2021 ; Al Homsi et al., 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Advances in the use of local anesthetic extended-release systems in pain management

Chen,

Xu,

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

Pain management remains among the most common and largely unmet clinical problems today. Local anesthetics play an indispensable role in pain management. The main limitation of traditional local anesthetics is the limited duration of a single injection. To address this problem, catheters are often placed or combined with other drugs in clinical practice to increase the time that local anesthetics act. However, this method does not meet the needs of clinical analgesics. Therefore, many researchers have worked to develop local anesthetic extended-release types that can be administered in a single dose. In recent years, drug extended-release systems have emerged dramatically due to their long duration and efficacy, providing more possibilities for the application of local anesthetics. This paper summarizes the types of local anesthetic drug delivery systems and their clinical applications, discusses them in the context of relevant studies on local anesthetics, and provides a summary and outlook on the development of local anesthetic extended-release agents.

show abstract

Section: Discussionmentioning

confidence: 99%

Advances in the use of local anesthetic extended-release systems in pain management

Chen,

Xu,

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…HTX-011 (Heron Therapeutics Inc.) has been approved by the US-FDA in 2021. 4 After injection at the wound site, there is controlled hydrolysis of the polymer leading to sustained release of both bupivacaine and meloxicam for the next 72 hours. It was earlier demonstrated that in acidic pH environments, which is present at the incision site due to inflammation, the efficacy of infiltrated bupivacaine is reduced.…”

mentioning

confidence: 99%